Compare ATLO & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | CMPX |
|---|---|---|
| Founded | 1903 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 927.5M |
| IPO Year | 2001 | 2020 |
| Metric | ATLO | CMPX |
|---|---|---|
| Price | $28.36 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.43 |
| AVG Volume (30 Days) | 39.0K | ★ 1.8M |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $677.91 |
| P/E Ratio | $74.63 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.33 | $1.40 |
| 52 Week High | $28.75 | $6.88 |
| Indicator | ATLO | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 67.85 | 49.44 |
| Support Level | $26.00 | $4.86 |
| Resistance Level | N/A | $5.77 |
| Average True Range (ATR) | 0.57 | 0.29 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 85.61 | 72.50 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.